State Street’s Immix Biopharma IMMX Stock Holding History

State Street’s Portfolio IMMX Stock Details IMMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.9M	Buy	2,996,935 +2,805,025	+1,462%	+$26M	﹤0.01%	2135
2026 Q1	$1.75M	Buy	191,910 +94,550	+97%	+$694K	﹤0.01%	3337
2025 Q4	$509K	Sell	97,360 -1,600	-2%	-$6.58K	﹤0.01%	3670
2025 Q3	$207K	Buy	98,960 +56,000	+130%	+$134K	﹤0.01%	3905
2025 Q2	$88.9K	Hold	42,960	–	–	﹤0.01%	3998
2025 Q1	$72.2K	Hold	42,960	–	–	﹤0.01%	4032
2024 Q4	$94.5K	Hold	42,960	–	–	﹤0.01%	3998
2024 Q3	$64K	Hold	42,960	–	–	﹤0.01%	4056
2024 Q2	$85.1K	Hold	42,960	–	–	﹤0.01%	4046
2024 Q1	$132K	Hold	42,960	–	–	﹤0.01%	3973
2023 Q4	$297K	Hold	42,960	–	–	﹤0.01%	3784
2023 Q3	$147K	Hold	42,960	–	–	﹤0.01%	4011
2023 Q2	$116K	Hold	42,960	–	–	﹤0.01%	4198
2023 Q1	$78.2K	Hold	42,960	–	–	﹤0.01%	4393
2022 Q4	$98.4K	Hold	42,960	–	–	﹤0.01%	4374
2022 Q3	$58K	Buy	42,960 +4,400	+11%	+$9.62K	﹤0.01%	4624
2022 Q2	$100K	Buy	+38,560	New	+$75.3K	﹤0.01%	4537

Other funds holding IMMX

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street's IMMX Position: Q2 2026 in Review

State Street increased its Immix Biopharma (IMMX) stake by 1,462% in Q2 2026, buying an estimated $26M and bringing the position to 2,996,935 shares worth $30.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2135.

State Street first reported a position in IMMX in Q2 2022 and has held it in 17 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

State Street held 2,996,935 shares of Immix Biopharma worth $30.9M as of Q2 2026.
State Street bought 2,805,025 Immix Biopharma shares in Q2 2026, an estimated $26M.
Immix Biopharma made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2135 holding.
State Street first reported a position in Immix Biopharma in Q2 2022 and has held it in 17 quarters since.
109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.